Key points

  • No antiviral or vaccine is approved for Crimean-Congo hemorrhagic fever, which has a 10-40% case fatality rate.
  • A screen of 108,947 compounds yielded 37 confirmed hits; three were studied in detail.
  • Compounds 11 and 14 cut infectious particle output more than 100-fold in cell culture.
  • The molecules act after viral entry and spare the host cell's own translation machinery.

Researchers hunting for a treatment for Crimean-Congo hemorrhagic fever have sifted through 108,947 chemical compounds and come away with three that block a key step in the virus's life cycle inside cultured cells. The work, led by Hoangvi Le and colleagues, appears in PLOS Pathogens.

Crimean-Congo hemorrhagic fever virus (CCHFV) spreads mainly through the bite of infected Hyalomma ticks, through contact with blood or tissue from infected livestock, and between people in healthcare settings. It is endemic in more than 30 countries across Africa, the Balkans, the Middle East, Central Asia and South Asia, and the case fatality rate ranges from 10% to 40%. No antiviral or vaccine has been approved for it.

The team went after the viral nucleocapsid protein, or N protein, which the virus uses to get its own messenger RNA translated ahead of the cell's. The N protein grips a hairpin-shaped fold in the mRNA using a region called the stalk domain. The researchers built a fluorescence-based assay to watch that grip form, then screened chemical libraries for molecules that loosen it. Primary screening flagged 122 inhibitors; 86 showed dose-dependent activity, and 37 were confirmed, with compounds 11, 14 and 33 taken forward. All three inhibited the protein-RNA interaction with IC50 values of 11-41 μM.

Against Hazara virus, a related virus used as a lower-biosafety stand-in for CCHFV, the compounds showed EC50 values of roughly 23-51 μM with little toxicity to the cells. Compounds 11 and 14 cut the output of infectious virus particles by more than 100-fold, and compound 33 nearly wiped out detectable infectious virus in the culture medium. The compounds acted after the virus had entered cells and selectively shut down N protein-driven translation of viral mRNA without disturbing the host's own translation machinery, the authors report. Modeling pointed to compound 11 binding at the stalk-head interface of the N protein.

Why it matters

The researchers say the protein-RNA interface they targeted is a workable drug target, offering a possible route to the first treatments for a tick-borne disease that currently has none.

What we don't know yet

The experiments were done in cell culture using Hazara virus as a surrogate for CCHFV, not in animals or people, and the compounds work at micromolar concentrations; the authors describe them as leads needing further optimization.

Terms in this story

Nucleocapsid (N) protein
A viral protein that coats the virus's genetic material and, in this virus, also helps its own messenger RNA get translated.
EC50
The concentration of a compound needed to produce half of its maximum effect, here against the virus in cells.
Surrogate virus
A less dangerous relative of a pathogen that can be studied in lower-containment labs to stand in for the real thing.

Sources and verification

  1. A new therapeutic opportunity in Crimean-Congo hemorrhagic fever: Targeting the stalk domain of viral nucleocapsid protein for therapeutic intervention PLOS · PLOS Pathogens · Nov 20, 2026 · peer-reviewed DOI: 10.1371/journal.ppat.1014772
Fact-checked against the source on November 21, 2026: 27 factual claims verified.
Written in our own words: longest phrase shared with the source is 9 words.
Related image from Wikimedia Commons (CC BY 2.0), checked for relevance and that it is not AI-generated. It is not an image from the study.

DexScience articles are produced with AI assistance and an automated fact-check against the linked sources. Spotted an error? Tell us and we will correct it openly.